Journal article · 2022 · Open access

PCR164 Patient-Reported Outcomes Validated in Phase 3 Clinical Trials: A Targeted Literature Review

Antonia Morga, Silvia Dibenedetto, Rocco Adiutori, Jinpeng Su

Value in Health, 25(7), S572 · Published 25 June 2022 · DOI 10.1016/j.jval.2022.04.1507

Open PDFView at the publisherCite this paper

In brief

“PCR164 Patient-Reported Outcomes Validated in Phase 3 Clinical Trials: A Targeted Literature Review” is a 2022 journal article by Antonia Morga and 3 co-authors, published in Value in Health. OpenAlex counts 0 citations as of 22 November 2026. It is open access: the full text is free to read at Value in Health.

Citations
0
Authors
4

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Morga, A., Dibenedetto, S., Adiutori, R., & Su, J. (2022). PCR164 Patient-Reported Outcomes Validated in Phase 3 Clinical Trials: A Targeted Literature Review. Value in Health, 25(7), S572. https://doi.org/10.1016/j.jval.2022.04.1507

MLA 9

Morga, Antonia, et al. “PCR164 Patient-Reported Outcomes Validated in Phase 3 Clinical Trials: A Targeted Literature Review.” Value in Health, vol. 25, no. 7, 2022, p. S572. https://doi.org/10.1016/j.jval.2022.04.1507.

Chicago

Morga, Antonia, Silvia Dibenedetto, Rocco Adiutori, and Jinpeng Su. 2022. “PCR164 Patient-Reported Outcomes Validated in Phase 3 Clinical Trials: A Targeted Literature Review.” Value in Health 25 (7): S572. https://doi.org/10.1016/j.jval.2022.04.1507.

Harvard

Morga, A. et al. (2022) ‘PCR164 Patient-Reported Outcomes Validated in Phase 3 Clinical Trials: A Targeted Literature Review’, Value in Health, 25(7), p. S572. doi:10.1016/j.jval.2022.04.1507.

IEEE

A. Morga, S. Dibenedetto, R. Adiutori, and J. Su, “PCR164 Patient-Reported Outcomes Validated in Phase 3 Clinical Trials: A Targeted Literature Review,” Value in Health, vol. 25, no. 7, p. S572, 2022, doi: 10.1016/j.jval.2022.04.1507.

BibTeX

@article{morga2022patient,
  title     = {{PCR164 Patient-Reported Outcomes Validated in Phase 3 Clinical Trials: A Targeted Literature Review}},
  author    = {Morga, Antonia and Dibenedetto, Silvia and Adiutori, Rocco and Su, Jinpeng},
  journal   = {Value in Health},
  year      = {2022},
  volume    = {25},
  number    = {7},
  pages     = {S572},
  doi       = {10.1016/j.jval.2022.04.1507},
  url       = {https://doi.org/10.1016/j.jval.2022.04.1507}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life

  • patient-reported outcomes
  • psychometric validation
  • minimal important difference
  • internal consistency
  • known-groups validity
  • responsiveness
  • concurrent validity
  • oral mucositis

Work with this paper

Most-cited papers in Economics, Econometrics and Finance

All highly cited Economics, Econometrics and Finance papers

Questions about this paper

How do I cite this paper in APA style?

Morga, A., Dibenedetto, S., Adiutori, R., & Su, J. (2022). PCR164 Patient-Reported Outcomes Validated in Phase 3 Clinical Trials: A Targeted Literature Review. Value in Health, 25(7), S572. https://doi.org/10.1016/j.jval.2022.04.1507

How many times has this paper been cited?

0 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Value in Health: sign in and open the PDF from this page.

Who wrote this paper?

Antonia Morga, Silvia Dibenedetto, Rocco Adiutori, Jinpeng Su.

What is the DOI of this paper?

10.1016/j.jval.2022.04.1507, permanently at https://doi.org/10.1016/j.jval.2022.04.1507. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.